zoukankan      html  css  js  c++  java
  • 抗TNF治疗的397例AS患者中,CRP和脊柱外受累对 ASDAS疗效的影响

    原文

    译文

    The Role of CRP and Peripheral Disease in Achieving ASDAS Response to Anti-TNF Therapy in 397 Patients with Ankylosing Spondylitis

     

    Karen Minde Fagerli 1, Elisabeth Lie2, D.M.F.M. van der Heijde3, Marte S. Heiberg1, Erik Rødevand4, Cecillie Kaufmann5, Knut Mikkelsen6, Synnøve Kalstad7 and Tore K. Kvien2, 1Diakonhjemmet hospital, Oslo, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3Leiden University Medical Center, Leiden, Netherlands, 4Trondheim, Norway, 5Vestre Viken, Drammen, Norway, 6Lillehammer Hosp for Rheumatic Diseases, Lillehammer, Norway, 7Tromsø, Norway

     

    Presentation Number: 531

     

    Background/Purpose: BASDAI has been the most commonly used outcome measure for assessing efficacy of TNF-inhibitors (TNFi) in ankylosing spondylitis (AS). However, BASDAI is solely patient-reported. ASDAS is a recently developed composite disease activity score incorporating an inflammatory marker (CRP or ESR). It has not been well studied if ASDAS performs similarly in patients with elevated CRP vs. normal CRP and patients with swollen joints vs. patients without swollen joints.

    Objective: To compare the response to TNFi according to different response criteria in patients with and without swollen joints as well as with and without elevated CRP.

    Method:  Data for these analyses were extracted from the NOR-DMARD register where adult patients with inflammatory arthropathies starting a new DMARD treatment have been consecutively included and followed longitudinally with assessments at 3, 6 and 12 months and then yearly. Patients with AS starting a TNFi who had complete data for calculating ASDAS-CRP at baseline and 3 months were selected for the current analyses. Cut-point for elevated CRP was selected as 10 mg/L. The presence of a swollen joint was based on evaluation of the 28-joint count as well as feet. Selected response criteria were ASDAS clinically important improvement (Δ ≥1.1), ASDAS major improvement (Δ ≥2.0), ASAS20, ASAS40, BASDAI50, BASDAI 2-point change and BASDAI response (BASDAI50 and/or BASDAI 2-point change).

    Result: 397 patients starting a TNFi were included in the analyses (70.2% males, 91.2% HLA B27 positive, mean (SD) age 42.7 (11.2) yrs, disease duration 11.8 (11.2) yrs, BASDAI 5.4 (2.1) and ASDAS 3.4 (1.1), median (IQR) CRP 9.0 (5.0-20.5) mg/L). 42.8% of patients had CRP levels ≥10 and 21.3% had at least one swollen joint. A significantly higher proportion of patients with a CRP ≥10 showed a response as compared to patients with a CRP <10 with all response criteria (table). This difference was most pronounced using ASDAS response criteria, but the % with ASDAS clinically important improvement in the patients with CRP < 10 was still in the same range as picked up with other response measures. When comparing the patients with or without swollen joints there was only a significant difference in achieving ASDAS major improvement.

    Conclusion: AS patients starting a TNFi who had a baseline CRP ≥10 more frequently achieved a response compared to patients with CRP <10. These findings were seen for ASDAS responses but also for measures that do not include inflammatory markers. The response rate for ASDAS clinically important improvement was similar to responses for other measures and the findings support the use of ASDAS as a response measure also in patients with normal CRP and without swollen joints.  

     

     

    TNF治疗的397AS患者中,CRP和脊柱外受累对 ASDAS疗效的影响

    Karen Minde Fagerli , et al. ACR 2011. Present No: 531

    背景/目的:BASDAI已成为强直性脊柱炎(AS) TNF抑制剂(TNFi)治疗最常用的疗效评价指标 。然而, BASDAI 完全是的病人主观报告。ASDAS则是近年来发展起来的综合疾病活动指数,其纳入了炎性指标(CRPESR)。 然而,CRP升高与否或关节肿胀与否的患者中, ASDAS应用的一致性尚未达到评估。

    摘要目的: 根据不同疗效标准,比较有或无肿胀关节和有或无CRP升高的患者对TNFi治疗的效果。

    方法:本研究数据来自成人炎症关节病的 NOR-DMARD登记系统,连续纳入开始新DMARD治疗的患者并持续随访,并在3个月、6个月、12个月以及随后每年进行相应评估。选择开始TNFi治疗的AS患者中有完整数据可计算基线和3个月ASDAS-CRP的进行分析。CRP增高的界定值定为10mg/L。肿胀关节的有无以28关节计数为基础。所选的疗效标准为ASDAS临床重要改善(≥1.1),ASDAS显著改善(≥2.0),ASAS20,ASAS40,BASDAI50,BASDAI 2分改善和BASDAI反应(BASDAI50/BASDAI 2分变化)

    结果:共纳入397例开始TNFi治疗的患者 (70.2%男性,91.2% HLA B27阳性,平均(SD)年龄42.7(11.2),病程11.8(11.2),BASDAI 5.4(2.1), ASDAS 3.4(1.1),中位数(IQR) CRP 9.0(5.0 - -20.5) mg/L)42.8%的患者CRP水平≥10, 21.3%的患者至少有一个肿胀关节。CRP≥10的患者所有的疗效指标有效率均显著高于CRP<10的患者 ()。这种差异在ASDAS疗效标准中最为显著,CRP< 10的患者群中ASDAS临床重要改善的%与其他疗效评价在同样的范围内。当比较有无关节肿胀患者时,仅ASDAS显著改善存在明显差异 。

    结论:开始TNFi治疗的AS患者,基线水平CRP≥10CRP< 10的患者更易有效。该结果可见于ASDAS疗效指标和不包括炎症标记的评价指标。ASDAS 临床重要改善的比例与其他标准相似,结果支持ASDAS作为疗效评价指标,其在CRP正常和无肿胀关节的患者中同样有效。

    Table: Percentages achieving response according to different criteria

     

    Overall

    CRP

    mg/L)

    Swollen joints

     

     

    ≥10

    <10

    p-value*

    Present

    Absent

    p-value*

    ASDAS clinically important improvement

    52.4

    75.3

    35.2

    <0.001

    56.1

    50.2

    0.38

    ASDAS major improvement

    26.7

    44.1

    13.7

    <0.001

    39.0

    22.8

    0.004

    ASAS 20

     

    61.4

    61.8

    43.6

    <0.001

    53.7

    50.2

    0.62

    ASAS 40

     

    36.0

    44.1

    30.0

    0.004

    40.2

    34.7

    0.37

    BASDAI 50

    43.1

    50.6

    37.4

    0.01

    43.2

    40.2

    0.71

    BASDAI 2 points

    49.4

    57.6

    43.2

    0.005

    56.1

    46.9

    0.17

    BASDAI response

    54.2

    61.8

    48.5

    0.01

    57.3

    52.5

    0.46

    *Chi-square test.

     

  • 相关阅读:
    AndRodi Strudio中的按钮时件
    Intent(三)向下一个活动传递数据
    Intent(二)隐式调用intent
    用PopupWindow做下拉框
    环形进度条
    Android Studio分类整理res/Layout中的布局文件(创建子目录)
    Android无需申请权限拨打电话
    使用ViewPager切换Fragment时,防止频繁调用OnCreatView
    定制 黑色描边、白色背景、带圆角 的背景
    Android 底部弹出Dialog(横向满屏)
  • 原文地址:https://www.cnblogs.com/T2T4RD/p/5464212.html
Copyright © 2011-2022 走看看